Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797064 | 0.90 | GAA (0.43) | TRPA1ADORA2AGAAMETHIF1A | |
| SCHEMBL7112394 | 0.85 | ADORA2A (0.39) | TRPA1CFTRALOX5APADORA2AGAA | |
| SCHEMBL6796275 | 0.83 | KMT2A (0.47) | TRPA1GAAHIF1AALDH1A1SMN1; SMN2 | |
| SCHEMBL6801426 | 0.83 | MCHR1 (0.39) | TRPA1ADORA2AGAAMETHIF1A | |
| SCHEMBL6549287 | 0.82 | GAA (0.40) | TRPA1ADORA2AGAAMETHIF1A | |
| SCHEMBL6547901 | 0.82 | GAA (0.39) | TRPA1ALOX5APADORA2AGAAMET | |
| SCHEMBL6549488 | 0.82 | PDE5A (0.45) | GAAHIF1AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL6550065 | 0.82 | MMP13 (0.42) | TRPA1ADORA2AGAAHIF1AALDH1A1 | |
| SCHEMBL6548972 | 0.82 | GAA (0.41) | GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6549145 | 0.81 | GAA (0.52) | TRPA1GAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138212-A1 | Disubstituted 1,7-guanines | PHARMACIA ITALIA, S.P.A. (IT) | 2004-07-15 | — | — | US | claimed |
| US-20040138212-A1 | Disubstituted 1,7-guanines | PHARMACIA ITALIA, S.P.A. (IT) | 2004-07-15 | — | — | US | disclosed |
| EP-1383766-A1 | DISUBSTITUTED 1,7-GUANINES | Pharmacia Italia S.p.A. (IT) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002090357-A1 | DISUBSTITUTED 1,7-GUANINES | PHARMACIA ITALIA S.P.A. (IT) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138212-A1 | Disubstituted 1,7-guanines | GDA, UNG, TYMS | TRPA1 4882/4885CFTR 3521/4885ALOX5AP 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.